Follow this innovation
[ via 
] [?]
Small Molecule Therapy for Obesity, Dyslipidemia, and Metabolic Disease
University of California System: University of California, San Francisco
posted on 11/19/2009
BACKGROUND: Cardiovascular disorders are leading causes of death worldwide and products have been developed to treat several of their addressable risk factors. Today’s market for anti-hypertensive agents is $35 billion and dyslipidemia treatments is $30 billion. While these therapies have been effective in the majority of patients in lowering blood pressure and LDL (low-density lipoprotein), they do not address other major cardiovascular risk factors such as obesity, liproprotein (a), HDL (high-density lipoprotein), and triglyceride levels. There is an unmet need for new agents that can be used alone or in combination with existing therapies to address these more elusive risk factors. DESCRIPTION: Researchers at University of California San Francisco and Oregon Health Sciences University have discovered a new class of thyroid hormone metabolites. The most potent of these, 3-iodothyronamine, has been shown in animal studies to completely switch fuel utilization away from carbohydrates and toward lipids. In single dose hamster studies this lipid-burning effect was sustained for 24 hours, several hours after the compound had been excreted. Further studies showed both reduced LDL and significant weight loss that was selective for fat mass vs. lean mass. 3-iodothyronamine is known to be an endogenous chemical derivative of thyroid hormone, a key hormone in regulating basal metabolic rate, protein synthesis, bone growth, neuronal maturation, and metabolism of lipids and carbohydrates.
Suggested Uses
Treatment of obesity, dyslipidemia, and metabolic disease
Advantages
- Animal studies indicate 3-iodothyronamine has both weight reducing effects as well as LDL-lowering capabilities
- Natural occurrence as a thyroid hormone derivative points toward favorable toxicity profile
- Unlike thyroid hormone, 3-iodothyronamine does not increase heart rate
File Number: 20027
Disease: Cardiovascular and Circulatory System
| Patent Number(s): | 6979750, 7321065, 7355079, 7339079, 2009/0105347 |
|---|---|
| Copyright: | ©2009-2010, The Regents of the University of California |
This innovation currently is not available for online licensing. Please contact Felice Lu at University of California System: University of California, San Francisco for more information.
request more info
ProfileFind more innovations
